Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors

The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.

Inclusion Criteria:

• Males and females age 18 years or older at time of locally advanced or metastatic diagnosis
• Patients with a confirmed diagnosis of locally advanced or metastatic Gastroenteropancreatic neuroendocrine tumour (GEP-NET)
• Patients who switched treatment from long acting octreotide LAR to lanreotide, where both treatments were received for the treatment of locally advanced or metastatic GEP-NET. i. Treatment with long acting octreotide LAR monotherapy for at least 90-days before treatment with lanreotide monotherapy (rescue SSA# use permitted). ii. Treatment with lanreotide monotherapy for at least 90-days after treatment with long acting octreotide monotherapy (rescue SSA# use permitted)

Exclusion Criteria:

• Patients with other malignant disease
• Patients who participated in a concomitant clinical trial related to treatment of GEP-NET
• Patients being treated with a Somatostatin analogue (SSA) in combination with other NET treatments excluding rescue SSA#
• Patients who received other primary treatment (e.g., targeted therapy, chemotherapy) for GEP-NET during the interval between octreotide and lanreotide
• Patients with NET familial genetic syndrome (i.e., MEN1)